CONTACT:Patrick O'BrienSenior Vice President, Investor RelationsCoherus BioSciences, Inc.email@example.com+1 (650) 649-3527
REDWOOD CITY, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2016 financial results will be released after market close on Monday, March 13, 2017. At 4:30 p.m. Eastern Time, Coherus' management will host a conference call to discuss the financial results and provide a general business update. After releasing fourth quarter and full year 2016 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com. Conference Call Information When: Monday, March 13, 2017 at 4:30 p.m. ET Dial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International) Conference ID: 66529524 Webcast: http://investors.coherus.com Please join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website. About Coherus BioSciences, Inc. Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.